Shield Therapeutics PLC Notice of Results (8030Y)

TIDMSTX

RNS Number : 8030Y

Shield Therapeutics PLC

14 September 2020

Shield Therapeutics plc

("Shield" or the "Group" or the "Company")

Notice of Results

Analyst and Investor Briefings

London, UK, 14 September 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru (R) /Accrufer (R) (ferric maltol), will announce its interim results for the six months ended 30 June 2020 on Wednesday 16 September 2020.

Analyst briefing

A briefing open to analysts will take place remotely via video conference call on Wednesday 16 September 2020 at 11.00am. If you would like the details of this call please contact Walbrook PR on [e-mail] .

Investor briefing

Shield Therapeutics will be hosting a live online presentation open to all investors on Wednesday 16 September at 4.30pm. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on the recent developments and additionally providing an update on the business.

The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via the following link:

https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor

For those investors who have already registered and added to meet the Company, they will automatically be invited.

Questions can be submitted pre-event via your Investor Meet Company dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will aim to address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

For further information please contact:

 
 Shield Therapeutics plc                             www.shieldtherapeutics.com 
 Tim Watts, CEO                                             [phone] 
 Karen Chandler Smith, Investor 
  Relations 
 
   Nominated Adviser and Joint 
   Broker 
 Peel Hunt LLP 
 James Steel/Dr Christopher 
  Golden                                                    [phone] 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/Matt Radley/Alice 
   Lane                                                     [phone] 
 
  Financial PR & IR Advisor 
 Walbrook PR                       [phone] or [e-mail] 
                                          [phone] / [phone] 
 Paul McManus/Lianne Cawthorne                                              303 
 

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru(R)/Accrufer(R), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORBUGDCSDBDGGB

(END) Dow Jones Newswires

September 14, 2020 02:00 ET (06:00 GMT)